Biogen Shares Spike on Alzheimer's Update
The first new drug application for an experimental therapy meant to prevent Alzheimer's disease from worsening finally reached regulators on Wednesday. Biogen (NASDAQ: BIIB) has finally submitted a biologics license application (BLA) for aducanumab, a monthly infusion that prevents amyloid plaques from forming in the brain. The Food and Drug Administration has 60 days to let Biogen know if it will review the aducanumab BLA in any form.